Lynn Anne Bristol

Array ( [id] => 11457162 [patent_doc_number] => 20170051069 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-23 [patent_title] => 'ANTI-CD134 (OX40) ANTIBODIES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/247425 [patent_app_country] => US [patent_app_date] => 2016-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 30 [patent_no_of_words] => 27549 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15247425 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16353140 [patent_doc_number] => 10793641 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-10-06 [patent_title] => Fully human anti-mesothelin antibodies and immune effector cells targeting mesothelin [patent_app_type] => utility [patent_app_number] => 15/754076 [patent_app_country] => US [patent_app_date] => 2016-08-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 10 [patent_no_of_words] => 11542 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 292 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15754076 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13733231 [patent_doc_number] => 20180371083 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-27 [patent_title] => ANTI-TIGIT ANTIBODIES [patent_app_type] => utility [patent_app_number] => 15/751618 [patent_app_country] => US [patent_app_date] => 2016-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39114 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15751618 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13793385 [patent_doc_number] => 20190010231 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-10 [patent_title] => NOVEL FUSION POLYPEPTIDE SPECIFIC FOR LAG-3 AND PD-1 [patent_app_type] => utility [patent_app_number] => 15/750651 [patent_app_country] => US [patent_app_date] => 2016-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23754 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -38 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15750651 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11457139 [patent_doc_number] => 20170051044 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-23 [patent_title] => 'ANTIGEN BINDING CONSTRUCTS TO TARGET MOLECULES' [patent_app_type] => utility [patent_app_number] => 15/228616 [patent_app_country] => US [patent_app_date] => 2016-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 157 [patent_figures_cnt] => 157 [patent_no_of_words] => 61673 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15228616 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11457139 [patent_doc_number] => 20170051044 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-23 [patent_title] => 'ANTIGEN BINDING CONSTRUCTS TO TARGET MOLECULES' [patent_app_type] => utility [patent_app_number] => 15/228616 [patent_app_country] => US [patent_app_date] => 2016-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 157 [patent_figures_cnt] => 157 [patent_no_of_words] => 61673 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15228616 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11457139 [patent_doc_number] => 20170051044 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-23 [patent_title] => 'ANTIGEN BINDING CONSTRUCTS TO TARGET MOLECULES' [patent_app_type] => utility [patent_app_number] => 15/228616 [patent_app_country] => US [patent_app_date] => 2016-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 157 [patent_figures_cnt] => 157 [patent_no_of_words] => 61673 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15228616 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11457139 [patent_doc_number] => 20170051044 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-23 [patent_title] => 'ANTIGEN BINDING CONSTRUCTS TO TARGET MOLECULES' [patent_app_type] => utility [patent_app_number] => 15/228616 [patent_app_country] => US [patent_app_date] => 2016-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 157 [patent_figures_cnt] => 157 [patent_no_of_words] => 61673 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15228616 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13551893 [patent_doc_number] => 20180327494 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-15 [patent_title] => SINGLE DOMAIN ANTIBODY AND DERIVATIVE PROTEINS THEREOF AGAINST PROGRAMMED DEATH-LIGAND (PDL1) [patent_app_type] => utility [patent_app_number] => 15/748421 [patent_app_country] => US [patent_app_date] => 2016-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20668 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15748421 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11421360 [patent_doc_number] => 20170029502 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-02 [patent_title] => 'ANTIBODY CONSTRUCTS FOR MSLN AND CD3' [patent_app_type] => utility [patent_app_number] => 15/225423 [patent_app_country] => US [patent_app_date] => 2016-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 50631 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15225423 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11129271 [patent_doc_number] => 20160326246 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-10 [patent_title] => 'Method for Regulating Cell Proliferation' [patent_app_type] => utility [patent_app_number] => 15/221822 [patent_app_country] => US [patent_app_date] => 2016-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 13354 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15221822 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13328587 [patent_doc_number] => 20180215831 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-02 [patent_title] => Antibody Derivatives with Conditionally Enabled Effector Function [patent_app_type] => utility [patent_app_number] => 15/748083 [patent_app_country] => US [patent_app_date] => 2016-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34473 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15748083 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11113641 [patent_doc_number] => 20160310613 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-27 [patent_title] => 'METHODS AND COMPOSITIONS FOR OVERCOMING DRUG-RESISTANCE IN CANCER BY TARGETED DELIVERY OF PRO-DRUG-NANO-POLYMERS' [patent_app_type] => utility [patent_app_number] => 15/196968 [patent_app_country] => US [patent_app_date] => 2016-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 15927 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15196968 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18384680 [patent_doc_number] => 11655452 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-23 [patent_title] => Chimeric antigen receptors (CARs), compositions and methods of use thereof [patent_app_type] => utility [patent_app_number] => 15/739596 [patent_app_country] => US [patent_app_date] => 2016-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 69 [patent_figures_cnt] => 74 [patent_no_of_words] => 27156 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 312 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15739596 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11649215 [patent_doc_number] => 20170145115 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-25 [patent_title] => 'Production of T cell retargeting hetero-dimeric immunoglobulins' [patent_app_type] => utility [patent_app_number] => 15/190268 [patent_app_country] => US [patent_app_date] => 2016-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 66 [patent_figures_cnt] => 66 [patent_no_of_words] => 53780 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15190268 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16800219 [patent_doc_number] => 10995140 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-05-04 [patent_title] => GM-CSF/CD40L vaccine and checkpoint inhibitor combination therapy [patent_app_type] => utility [patent_app_number] => 15/579311 [patent_app_country] => US [patent_app_date] => 2016-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 12 [patent_no_of_words] => 32616 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15579311 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13168015 [patent_doc_number] => 10100111 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-10-16 [patent_title] => Stable and soluble antibodies inhibiting TNF alpha [patent_app_type] => utility [patent_app_number] => 15/157641 [patent_app_country] => US [patent_app_date] => 2016-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 17 [patent_no_of_words] => 19615 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 326 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15157641 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11336735 [patent_doc_number] => 20160362490 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-15 [patent_title] => 'ANTI-CD33 ANTIBODIES AND METHODS FOR TREATMENT OF ACUTE MYELOID LEUKEMIA USING THE SAME' [patent_app_type] => utility [patent_app_number] => 15/154115 [patent_app_country] => US [patent_app_date] => 2016-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 18425 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15154115 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12766333 [patent_doc_number] => 20180147279 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-31 [patent_title] => COMBINATION THERAPY FOR NON-SMALL CELL LUNG CANCER POSITIVE FOR EGFR MUTATION [patent_app_type] => utility [patent_app_number] => 15/568586 [patent_app_country] => US [patent_app_date] => 2016-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8438 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15568586 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11113619 [patent_doc_number] => 20160310591 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-27 [patent_title] => 'METHODS AND COMPOSITIONS FOR OVERCOMING DRUG-RESISTANCE IN CANCER BY TARGETED DELIVERY OF PRO-DRUG-NANO-POLYMERS' [patent_app_type] => utility [patent_app_number] => 15/135543 [patent_app_country] => US [patent_app_date] => 2016-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 15551 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15135543 [rel_patent_id] =>[rel_patent_doc_number] =>)